Idexx Laboratories, Inc [IDXX] stock prices are up 1.72% to $549.97 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IDXX shares have gain 6.03% over the last week, with a monthly amount glided 3.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Idexx Laboratories, Inc [NASDAQ: IDXX] stock has seen the most recent analyst activity on July 01, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $625. Previously, Leerink Partners started tracking the stock with Outperform rating on December 02, 2024, and set its price target to $500. On July 25, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $580 on the stock. Piper Sandler downgraded its rating to a Neutral but stick to its price target of $525 on January 30, 2024. Exane BNP Paribas initiated its recommendation with a Outperform and recommended $602 as its price target on December 07, 2023. Cleveland Research upgraded its rating to Buy for this stock on December 04, 2023. In a note dated August 02, 2023, Atlantic Equities downgraded an Neutral rating on this stock but restated the target price of $610.
The stock price of Idexx Laboratories, Inc [IDXX] has been fluctuating between $356.14 and $549.52 over the past year. Currently, Wall Street analysts expect the stock to reach $479.75 within the next 12 months. Idexx Laboratories, Inc [NASDAQ: IDXX] shares were valued at $549.97 at the most recent close of the market. An investor can expect a potential drop of -12.77% based on the average IDXX price forecast.
Analyzing the IDXX fundamentals
The Idexx Laboratories, Inc [NASDAQ:IDXX] reported sales of 3.93B for trailing twelve months, representing a surge of 3.56%. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.29%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.28, Equity is 0.57 and Total Capital is 0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 541.30 points at the first support level, and at 532.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 554.87, and for the 2nd resistance point, it is at 559.77.
Ratios To Look Out For
It’s worth pointing out that Idexx Laboratories, Inc [NASDAQ:IDXX]’s Current Ratio is 1.10. In addition, the Quick Ratio stands at 0.76 and the Cash Ratio stands at 0.14. Considering the valuation of this stock, the price to sales ratio is 11.25, the price to book ratio is 30.67 and price to earnings (TTM) ratio is 50.82.
Transactions by insiders
Recent insider trading involved SZOSTAK M ANNE, Director, that happened on May 21 ’25 when 1260.0 shares were sold. Director, SZOSTAK M ANNE completed a deal on May 21 ’25 to sell 1046.0 shares. Meanwhile, Director SZOSTAK M ANNE bought 1260.0 shares on May 21 ’25.
